Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Comments
Loading...
  • Health Canada has approved Moderna Inc's MRNA mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years.
  • The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union.
  • "Health Canada was the first regulator to approve our COVID-19 vaccine fully. We are pleased they have taken this important step to expand this authorization to children aged 6 to11 years," said Stéphane Bancel, Chief Executive Officer of Moderna. 
  • Also Read: Alnylam Pharmaceuticals Files Patent Infringement Suits Against Pfizer And Moderna.
  • Moderna's vaccine was investigated in the ongoing Phase 2/3 KidCOVE study. 
  • Data submitted to Health Canada from over 4,000 children demonstrated that vaccination with a 50 μg mRNA-1273 was non-inferior in anti-SARS-CoV-2 neutralizing antibody responses compared to 18 to 25 years old from the Phase 3 COVE study. 
  • Price Action: MRNA shares are down 1.15% at $167.42 during the market session on the last check Thursday.
  • Photo by mufidpwt via Pixaby
MRNA Logo
MRNAModerna Inc
$24.25-5.42%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
5.20
Growth
-
Quality
-
Value
65.73
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: